United Kingdom
United Kingdom

The 'go to' European specialist pharma company


Norgine logos through the years



In March 2017, Norgine entered into an agreement with Noventure S.L., under which Norgine will distribute GELSECTAN® in Spain, Portugal and Andorra.



  • In August 2016, Norgine licensed NER1006 (PLENVU) to Valeant Pharmaceuticals in US and Canada
  • In June 2016, Norgine divested its MENA operations and product rights to Acino.
  • Norgine and its subsidiary Arc Medical Design Ltd entered into a distribution agreement with Olympus Corporation of the Americas as the exclusive distributor of ENDOCUFF VISION® in the US and Canada.
  • Norgine expands its partnership with A Pharm s.r.l. to distribute ZIVEREL® in Austria, Belgium, Denmark, Finland, Germany, Ireland, Luxembourg, the Netherlands, Norway, Sweden, Switzerland and the UK.



  • Norgine and Navidea enter European partnership for LYMPHOSEEK®.
  • Norgine partners with Arc Medical Design Ltd. for endoscopic device, ENDOCUFF VISION®.
  • Norgine B.V. acquires a 70% stake in Arc Medical Design Ltd.
  • Norgine entered an agreement with Apharm s.r.l. to distribute ZIVEREL® in Spain, Australia and New Zealand.

  • Norgine divests its Southern African operations and product rights to Aspen.




  • SpePharm AG, an affiliate of Norgine B.V sells SAVENE® (dexrazoxane) to Clinigen Group plc.
  • Norgine in-licenses MUGARD®  from Access Pharmaceuticals Inc. in Europe for the prevention and management of the lesions and symptoms of oral mucositis.
  • Norgine signs expanded licensing agreement with PlasmaTech Biopharmaceuticals for MUGARD® to now include Australia and New Zealand.
  • Norgine partners with China Medical Systems Holdings Limited for MOVICOL® in China.



  • EU Launch of XIFAXAN® 550
  • EU Launch of SETOFILM®
  • MOVIPREP®  launched in Japan, Kazakhstan, Ukraine and India
  • OBLEAN® approved in Japan
  • In-licenses ICEF15 (Ph. IIb) for faecal incontinence from Innovacell

ICEF15 process


  • Launch of GIPROCOL®
  • XIFAXAN® 550 approved in Australia and Europe for hepatic encephalopathy
  • Creates SpePharm AG JV and acquires additional supportive care products
  • Launch of Norgine Ventures


  • Out-licenses MOVIPREP® to Nycomed in the CIS
  • Enters partnership with Alimentary Health on development of medicinal products using AH technology
  • Enters into a discovery partnership with Jubilant to develop multiple targets utilising Jubilant Biosys integrated drug discovery platform targeting gastrointestinal diseases.
  • In-licenses exclusive rights to SETOFILM® (Ondansetron RapidFilm) for Europe, MENA, Southern Africa and Australasia from APR
  • Stopped the development of ZEGERID® and ulimorelin


  • In-licenses ulimorelin (TZP-101) in Europe, Australia, New Zealand, the Middle East, South Africa and North Africa, in June from Tranzyme Pharma
  • In November, Norgine acquires 12.7% of the issued share capital in ProStrakan Group plc
  • Opening Middle East office in Cairo

Middle East flag


  • Out-licenses MOVIPREP® to PharmaSwiss in Eastern Europe
  • In-licenses exclusive worldwide patent portfolio from L’Institut National Recherche Agronomique (INRA)
  • In-licenses ZEGERID® from Santarus
  • Acquires  CAMETOR® / OBLEAN® (cetilistat) from Alizyme Therapeutics Ltd


  • In-licenses COLAL-PRED in Europe, South Africa, Australia and New Zealand from Alizyme Therapeutics Ltd
  • Partners with Ajinomoto to develop, manufacture and market MOVIPREP® in Japan
  • Out-licenses MOVIPREP®  to Medical Futures in Canada
  • In-licenses XIFAXAN® from Alfa-Wasserman


  • MOVIPREP® approved by the FDA
  • Opens Scandinavian regional office in Copenhagen 


  • Launch of ORAMORPH®
  • Out-licenses MOVIPREP® to Salix Pharmaceuticals in the US


Launch of MOVICOL®


In-licenses KLEAN-PREP® from Birex Pharmaceuticals (now Helsinn Healthcare)


Acquires Camden Chemical Company (CAMCOLIT, SPASMONAL, KAMILLOSAN, WAXSOL)






—Norgine invested in two new manufacturing sites in Dreux (France) and Hengoed (Wales).
—New products launched during this decade included NORMACOL® enema, NORTUSSINE® (a cough syrup), GIVALEX® (a mouthwash) and CONTRACIDE® (an antacid).


1930 to 50

  • —Victor Stein died in 1934 and he was succeeded by his brother Oswald and his nephew Walter
  • —Norgine was largely dormant during World War II
  • —At the end of World War II, Walter Stein returned from South America and revived Norgine
  • —Manufacturing resumed in Argenteuil (France) and London—

1930 to 50


Prof Emil Starkenstein

Prof. Emil Starkenstein the ‘Father of Pharmacology’ was an early academic collaborator with Norgine

  • —Norgine was the first company in central Europe to manufacture insulin—
  • —Norgine worked with leading academic groups throughout central Europe—
  • —Norgine developed drug delivery technology before the term existed—
  • —Norgine established its own subsidiaries in France, Germany, Belgium and the UK


  • —Established by Dr Victor Stein in Prague, Czechoslovakia
  • Its first —product was Sodium Alginate extracted from seaweed for use in the manufacture of paper
  • Discovered the best seaweed came from the Nordic regions.
  • Norgine – Nor  comes from Nordic and Gine from Alginate.
  • Sailboat symbol represents the collection of raw materials. 


Viktor Stein